a Department of Pharmacy Practice, School of Pharmacy, The University of Kansas Medical Center, Kansas City, KS 66160-7231 b Department of Pharmacy Research, Hartford Hospital, Hartford, CT 06102-5037, USA c Division of Infectious Diseases, Hartford Hospital, Hartford, CT 06102-5037, USA d Office of Research Administration, Hartford Hospital, Hartford, CT 06102-5037, USA
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Fluoroquinolone antibiotics are typically known for their excellent activity against Gram-negative pathogens. However, extended-spectrum fluoroquinolones with potent Gram-positive activity, such as trovafloxacin, have only recently become available. Trovafloxacin, a unique, synthetic fluoroquinolone with a long half-life, is characterized by its microbiological activity against anaerobes, Gram-negative and Gram-positive pathogens, including penicillin non-susceptible pneumococci.10 Typical MIC values of trovafloxacin for S. pneumoniaeare between four- and 32-fold lower than those reported for other fluoroquinolones such as ciprofloxacin and ofloxacin.11,12
The purpose of this study was to compare the protective effects of trovafloxacin, ciprofloxacin and ampicillin against penicillin-susceptible, -intermediate and -resistant isolates of S. pneumoniae using an intraperitoneal, immunocompetent mouse model of sepsis.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bacterial strains and susceptibility testing
Thirteen S. pneumoniae clinical isolates from Hartford Hospital and three isolates from Pfizer Laboratories were screened for susceptibility to penicillin, ampicillin, ciprofloxacin and trovafloxacin. MICs were determined in duplicate according to the National Committee for Clinical Laboratory Standards (NCCLS) using a microdilution technique and antimicrobial standard powders with known potencies.13 Cation-adjusted MuellerHinton broth (CAMHB, Becton Dickinson, Cockeysville, MD, USA) supplemented with 2.55% lysed horse blood (LHB, Remel, Lenexa, KS, USA) was used as the bacterial growth medium in all in-vitro studies. Three isolates were selected which displayed a range of susceptibility for penicillin and ampicillin: one strain each of penicillin-susceptible, -intermediate and -resistant S. pneumoniae.
Antibiotics
The following antibiotics were used in all in-vivo studies: ampicillin sodium salt standard powder (Sigma Chemical Company, St Louis, MO, USA (lot 076H0373)), ciprofloxacin iv injection, 40 g/L (Bayer Corporation, West Haven, CT, USA (lot 6LCA)) and trovafloxacin standard powder (Pfizer Laboratories, New York, NY, USA (lot 31075-199-1F)).
Preparation of bacterial suspensions
Fresh colonies of the test isolates were taken from tryptocasein-soy agar plates (100 mm) with 5% sheep blood (Becton Dickinson) after overnight growth and inoculated into CAMHB with LHB. The bacterial suspension was placed into a 5% CO2 incubator for 4 h before the start of all experiments. Colony forming unit (cfu) counts were verified by plating serially diluted aliquots on agar plates.
Animals
Immunocompetent Swiss Webster mice (Taconic Laboratory Animals and Services, Germantown, NY, USA) weighing approximately 25 g were used throughout this study. Animals were allowed, at least 72 h after delivery, to acclimatize to laboratory surroundings before experimentation.
Minimum lethal dose determination
The minimum lethal dose (MLD) was determined in duplicate for each study isolate. Groups of mice (n = 10) were injected ip with 0.5 mL of inocula ranging from 101 to 107 cfu/mL. The MLD inoculum was selected on the basis of 100% mortality at the end of 48 h. For each MLD determination, a control group of 10 mice received normal saline instead of the bacterial suspension.
Protective dose determination
The protective dose for 50% of the population (PD50) was determined in triplicate for each isolate over a 5 day study period. Groups of mice (n = 10) were infected ip with 0.5 mL of the test isolate MLD bacterial suspension. The mean weight of the animal population was determined within the immediate 24 h period before bacterial infection. Using the mean population weight, dose-ranging studies were performed. Antibiotic solutions were serially diluted and prepared such that 0.2 mL would contain the following range of concentrations: trovafloxacin 0.532 mg/kg, ciprofloxacin 164 mg/kg and ampicillin 0.25128 mg/kg. Antibiotics were administered as a single sc dose at the dorsal base of the neck 1 h after inoculation with bacteria. A group of 10 mice served as control for each experiment and received 0.2 mL of normal saline instead of antibiotic.
Determination of activity
Animals were observed a minimum of three times daily over a 5-day period after inoculation. The PD50 was calculated from the plot of survivors versus dose administered for each experiment using the Sigmoid Emax model.14
Statistical analysis
Protective dose data were compared between antimicrobials for each isolate using an analysis
of variance method followed by the Scheffe test for multiple comparisons. A P-value of
0.05 was considered significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The Table shows the pre-experimental MIC results of ampicillin, trovafloxacin and ciprofloxacin for the three selected S. pneumoniae isolates. The screening MIC values for penicillin for each isolate were as follows: SP22, 0.06; SP45, 0.125 and SP46, 4.
|
Mortality was not observed in any of the control groups at 48 h during any of the MLD determinations. The virulent study isolates had MLD values ranging from 102 (SP22 and SP45) to 104 (SP46) cfu/mL as shown in the Table.
Protective dose determinations
Plots of percentage survival versus dose (mg/kg) are shown in Figures 1, 2 and 3 and PD50 experimental results are presented in the Table. These data show that ampicillin had significantly lower PD50 values (range 1.02.7 mg/kg) for the PCN-S and PCN-I isolates when compared with either trovafloxacin (range 11.522.8 mg/kg) or ciprofloxacin (>64 mg/kg). Trovafloxacin gave PD50 values that were significantly lower than those of ciprofloxacin for all strains (10.822.8 mg/kg versus >64 mg/kg). For the penicillin-resistant isolate, trovafloxacin (10.8 mg/kg) was statistically superior to both ampicillin (>128 mg/kg) and ciprofloxacin (>64 mg/kg). Mortality was noted for all animals in the control groups at day 5, the majority having died within the immediate 48 h period following infection.
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The observed differences in microbiological activity between trovafloxacin and ciprofloxacin against S. pneumoniaemay be due to an additional enzyme target for trovafloxacin.10 Trovafloxacin has been found to inhibit both DNA gyrase and another type II topoisomerase, topoisomerase IV. The inhibition of topoisomerase IV is thought to confer enhanced potency against Gram-positive pathogens, such as S. pneumoniae.
Our group has previously shown that significantly lower PD50 values are observed for penicillin G compared with ciprofloxacin when using a similar murine model of pneumococcal sepsis.15 In this study, a penicillin-susceptible strain of S. pneumoniae was used with MICs of penicillin G and ciprofloxacin of 0.03 mg/L and 1.0 mg/L, respectively. The reported PD50 of penicillin G was 0.307 ± 0.325 mg/kg, and for ciprofloxacin it was 25.52 ± 1.95 mg/kg. The PD50 of ciprofloxacin was lower than the values observed in our present study, but in the study of Sullivan and colleagues, the animals received ciprofloxacin doses every 3 h for a total of eight doses. Additionally, in our study, all of the test strains had ciprofloxacin MIC values of 2 mg/L, which was higher than the MIC value of 1 mg/L used in the multidose ciprofloxacin study.
The activity of trovafloxacin and ciprofloxacin against S. pneumoniae has been evaluated in other in-vivo models including a rabbit model of meningitis,16,17 a systemic (intraperitoneal) sepsis model18 and a murine pneumonia model.18,19 Regardless of the model investigated, trovafloxacin has consistently been shown to be more active against pneumococcus than other fluoroquinolones, including ciprofloxacin.
Our results seem to correlate well with previously published reports of trovafloxacin efficacy and ciprofloxacin failure against S. pneumoniae in other in-vivo models.16,17,18,19 The effects of trovafloxacin against penicillin-resistant strains of S. pneumoniae may add to its clinical usefulness as penicillin resistance increases worldwide.
In summary, using a murine model of intraperitoneal sepsis, we have demonstrated that trovafloxacin has potent microbiological activity against S. pneumoniae compared with ciprofloxacin, regardless of penicillin susceptibility. However, when considering penicillin-susceptible and -intermediate strains, ampicillin displayed superior activity compared with trovafloxacin and ciprofloxacin.
![]() |
Acknowledgments |
---|
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 . Fine, M. J., Smith, M. A., Carson, C. A., Mutha, S. S., Sankey, S. S., Weissfeld, L. A. et al. (1996). Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. Journal of the American Medical Association 275, 13441.[Abstract]
3 . Gwaltney, J. M. (1996). Acute community-acquired sinusitis. Clinical Infectious Diseases 23, 120923.[ISI][Medline]
4
.
Schuchat A., Robinson, K., Wenger, J. D., Harrison, L.
H., Farley, M., Reingold A. L. et al. (1997). Bacterial meningitis in the
United States in 1995. New England Journal of Medicine 337, 9706.
5 . Doern, G. V., Brueggemann, A., Holley, H. P. & Rauch, A. (1996). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 19941995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 120813. [Abstract]
6 . Goldstein, F. W. & Acar, J. F. (1996). Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 199293 Western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 7184.[ISI][Medline]
7 . Simberkoff, M. S. (1994). Drug-resistant pneumococcal infections in the United States. A problem for clinicians, laboratories, and public health. Journal of the American Medical Association 271, 18756.[ISI][Medline]
8 . Thornsberry, C., Ogilvie, P., Kahn, J. & Mauriz, Y. (1997). Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 19961997 respiratory season. The Laboratory Investigator Group. Diagnostic Microbiology and Infectious Diseases 29, 24957. [ISI][Medline]
9 . Schreiber, J. R. & Jacobs, M. R. (1995). Antibiotic-resistant pneumococci. Pediatric Clinics of North America 42, 51937.[ISI][Medline]
10
.
Brighty, K. E. & Gootz, T. D. (1997). The chemistry and biological profile of trovafloxacin. Journal of Antimicrobial
Chemotherapy 39 Suppl. B, 114.
11 . Gootz, T. D., Zaniewski, R., Haskell, S., Schmieder, B., Tankovic, J., Girard, D. et al. (1996). Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrobial Agents and Chemotherapy 40, 26917.[Abstract]
12 . Klugman, K. & Wasas, A. (1995). In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 36, 8734.[ISI][Medline]
13 . National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow AerobicallyFourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA.
14 . Fantin, B., Leggett, J., Ebert, S. & Craig, W. A. (1991). Correlation between in vitro and in vivo activity of antimicrobial agents against Gram-negative bacilli in a murine infection model. Antimicrobial Agents and Chemotherapy 35, 141322.[ISI][Medline]
15 . Sullivan, M. C., Cooper, B. W., Nightingale, C. H., Quintiliani, R. & Lawlor, M. T. (1993). Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrobial Agents and Chemotherapy 37, 2349.[Abstract]
16 . Nau, R., Schmidt, T., Kaye, K., Froula, J. F. & Tauber, M. G. (1995). Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrobial Agents and Chemotherapy 39, 5937.[Abstract]
17 . Paris, M. M., Hickey, S. M., Trujillo, M., Shelton, S. & McCracken, G. H. (1995). Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 39, 12436.[Abstract]
18 . Girard, A. E., Girard, D., Gootz, T. D., Faiella, J. A. & Cimochowski, C. R. (1995). In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrobial Agents and Chemotherapy 39, 221016.[Abstract]
19 . Azoulay-Dupuis, E., Bedos, J. P., Bauchet, J., Reux, V., Muffat-Joly, M. & Carbon, C. (1996). Efficacy of trovafloxacin against penicillin-susceptible and resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract B43, p. 29. American Society for Microbiology, Washington, DC.
20 . Lacy, M. K., Nicolau, D. P., Banevicius, M. A., Nightingale, C. H. & Quintiliani, R. (1997). Protective effect of trovafloxacin, ciprofloxacin, and ampicillin against isolates of S. pneumoniae with varying penicillin susceptibilities. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Abstract B97, p. 44. American Society for Microbiology, Washington, DC.
Received 4 January 1999; returned 13 April 1999; revised 10 May 1999; accepted 27 May 1999